Breast Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
Select
13073B A Multi-Modality Surveillance Program for Women At High Risk for Breast Cancer
9127 Improved MRi Images of Breast Lesions (not all cancer patients)
Select
09-151-B A Pilot Study of Chemoprevention of Green Tea in Women with Ductal Carcinoma in Situ
15837A A Long Term Investigation of Curative Treatment in Breast Cancer Patients
10-136-A The Correlation of Radiographic Complete Response on Breast MRI with Pathologic Complete Response in Patients Receiving Neoadjuvant Systemic Treatment
Select
10-183-B Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial)
11365B Computer-Aided Diagnosis of Breast Lesions in Mammograms
16648A Pilot study of mammography-like breast ultrasound
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
11-0173 S1007:A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Select
11-0575 A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk
Select
11-0574 Pilot study to analyze a novel mechanism underlying response to tamoxifen therapy in breast cancer patients
Select
12-1173 A Double-blind, Randomized Phase II Trail of Active Immunotherapy with Globo H-KLH (OPT-822) in Subjects with Metastatic Breast Cancer
12-1229 Contralateral Prophylactic Mastectomy in Women Diagnosed with Ipsilateral Breast Cancer
12-1467 A Pilot Study Evaluating the Effects of Bariatric Surgery on Biomarkers of Breast Cancer Risk
12-2052 Improved Management of High Risk Breast Lesions with Quantitative MRI
Select
13-0418 S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer e3 Breast Cancer Study ¿ Evaluation Everolimus with Endocrine Therapy
Select
IRB13-0775 Validation of a Polygenic Neurotoxicity Risk Score in Patients with Unusually Severe Paclitaxel-Induced Neuropathy
Select
IRB13-0947 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal
IRB13-0921 Moving Forward: A weight loss intervention for African-American breast cancer survivors
Select
IRB13-1000 Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Select
IRB13-1194 A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease
IRB13-1337 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Select
IRB13-1365 A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Select
IRB13-1389 Phase I Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB13-1193 A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The ¿METRIC¿ Study)
Select
IRB14-0283 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Previously Treated Advanced or Metastatic HER2-negative Breast Cancer
IRB14-0461 Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.